Patents by Inventor Manuel Simonutti

Manuel Simonutti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160193166
    Abstract: The use of substance selected from taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation, and a pharmaceutical composition including the substance and the active ingredient.
    Type: Application
    Filed: February 23, 2016
    Publication date: July 7, 2016
    Inventors: Serge PICAUD, Jose Alain SAHEL, Jammoul FIRAS, Caroline CORIAT, Manuel SIMONUTTI
  • Patent number: 9308260
    Abstract: The use of substance selected from taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation, and a pharmaceutical composition including the substance and the active ingredient.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: April 12, 2016
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Serge Picaud, Jose Alain Sahel, Jammoul Firas, Caroline Coriat, Manuel Simonutti
  • Publication number: 20120157532
    Abstract: The present invention relates to a method of treating or preventing a convulsive disorder in a patient in need thereof comprising administering said patient with a therapeutically effective amount of an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation once per day in the evening or at night.
    Type: Application
    Filed: April 16, 2010
    Publication date: June 21, 2012
    Inventors: Serge Picaud, Jose-Alain Sahel, Manuel Simonutti, Firas Jammoul
  • Publication number: 20100184707
    Abstract: The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation.
    Type: Application
    Filed: July 4, 2008
    Publication date: July 22, 2010
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Serge Picaud, Jose Alain Sahel, Jammoul Firas, Caroline Coriat, Manuel Simonutti
  • Publication number: 20100062987
    Abstract: The present invention pertains to pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one glutamate receptor activating substance.
    Type: Application
    Filed: November 22, 2007
    Publication date: March 11, 2010
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale
    Inventors: Serge Picaud, Jose Sahel, Qinping Wang, Agnes Duboc, Manuel Simonutti
  • Publication number: 20090292021
    Abstract: Pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one substance having anti-ischemic effect, are disclosed.
    Type: Application
    Filed: July 31, 2007
    Publication date: November 26, 2009
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC
    Inventors: Serge Picaud, Agnes Duboc, Michel Paques, Jose Sahel, Manuel Simonutti